Completed Enrollment

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

J3N-OX-JZRA -

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Blood Cancers
What the trial is testing?
LOXO-338 / LY3847429, Pirtobruitinib
Could I receive a Placebo?
No
Enrollment Goal
316
Trial Dates
Sep 30, 2021 - Dec 1, 2023
How long will I be in the trial?
The study may last up to approximately 3 years.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have B-cell cancer that requires treatment, including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Waldenström macroglobulinemia, multiple myeloma and AL amyloidosis

  • Have already had treatment for B-cell cancer

  • Be well enough to walk and do light work

  • Have adequate organ function and blood counts, as measured by blood tests

  • Have recovered from the major side effects of prior cancer treatments

Participants Must Not:

  • Have active cancer that has spread to the brain or spinal cord

  • Have active infection

  • Be taking other cancer treatments

  • Take certain medicines that affect how fast the study drug is broken down in the body

  • Have serious heart disease

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources